The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah startup that aims ...

Cybin has unveiled phase 2 results with its psychedelic medicine for major depressive disorder that it says support moving ...

The UK pharma added Lokelma to its pipeline through its $2.7 billion acquisition of ZS Pharma in 2015. It competes in the ...

The FDA has kicked off a priority review of a new combination regimen for previously untreated, locally advanced or ...

ImmunoGen won accelerated FDA approval for folate receptor alpha (FRα)-directed Elahere a year ago, when it became the first ...

One promising avenue is the adoption of PCR, encompassing Pre-Consumer or Post-Consumer Recycled materials. This approach ...

After five years of painstaking lab work, more than 350,000 hours of genome sequencing and £200 million ($253 million) in ...

Bumpus is heading for the number two position at the FDA – second only to Commissioner Robert Califf, who announced the ...

Patients with very high levels of the biomarker of 80 mg/dL or more were found to have a 27% greater risk of developing ...

In this issue of Deep Dive, AXON’s Silvia De Carvalho details how generative AI is ushering in a new era of expedited, ...

New data for Astellas Pharma’s non-hormonal menopause therapy fezolinetant has shown it remains effective to 24 weeks, ...

The Ministry of Health, Labour and Welfare (MHLW) gave the green light to CSL and Arcturus’ COVID-19 vaccine ARCT-154 – also ...